5-[[4-[(1-Methyl-6-methylsulfanylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-[[4-[(1-Methyl-6-methylsulfanylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₀H₁₉N₃O₃S₂
• 分子量: 413.5
• InChiKey: IHRSHDLTIZFBNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Therapeutic and prophylactic agents for neoplasms
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20020137776A1

  公开（公告）日：2002-09-26

  This invention relates to therapeutic and prophylactic agents for neoplasms which comprise a fused heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient; to the use of such a compound in the preparation of a medicament for the treatment and prevention of neoplasms; and to a method for treatment and prevention of neoplasms which comprises administering a pharmaceutically effective amount of such a compound to a warm-blooded animal (preferably a human).

  本发明涉及治疗和预防肿瘤的治疗剂和预防剂，其包括融合的杂环化合物或其药学上可接受的盐作为活性成分；使用这种化合物制备治疗和预防肿瘤的药物；以及一种治疗和预防肿瘤的方法，其中将这种化合物的药学有效量注射到温血动物（最好是人类）中。
• PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER
  申请人：Sankyo Company, Limited

  公开号：EP1197211A1

  公开（公告）日：2002-04-17

  Fused heterocyclic compounds of formula (I): wherein X is benzimidazolyl which is optionally substituted with 1 to 5 substituents selected from Group A; Y is an oxygen or sulfur atom; Z is 2,4-dioxothiazolidin-5-ylmethyl or the like; R is hydrogen or the like; m is an integer from 1 to 5; and Group A is alkyl or the like; and pharmaceutically acceptable salts thereof are useful as therapeutic or prophylactic agents for cancer.

  式(I)的融合杂环化合物： 其中 X 是苯并咪唑基，可任选被 1 至 5 个选自 A 组的取代基取代；Y 是氧原子或硫原子；Z 是 2，4-二氧代噻唑啉-5-基甲基或类似物；R 是氢或类似物；m 是 1 至 5 的整数；A 组是烷基或类似物；其药学上可接受的盐类可用作癌症的治疗剂或预防剂。
• US6569877B2
  申请人：——

  公开号：US6569877B2

  公开（公告）日：2003-05-27